Ouça os comentários do Dr. Marwan Fakih sobre o gerenciamento das toxicidades observadas no SIRFLOX.

Principais comentários e conclusões do Dr. Fakih:

  • O número de neutropenias de grau 3 reportadas no estudo SIRFLOX não foi em si clinicamente significativo e não ficou longe do que foi observado em outros regimes de quimioterapia FOLFOX.
  • O Dr. Fakih comenta que os efeitos colaterais hematológicos da SIRT podem ser tratados pela redução da dose de oxaliplatina ou adicionando um fator de crescimento de leucócitos.
  • A maioria dos oncologistas interrompe a oxaliplatina depois do oitavo ciclo; porém, os pesquisadores do SIRFLOX continuaram com a oxaliplatina até o nível de progressão ou intolerância. O Dr. Fakih assume que a neutropenia foi parcialmente causada por um efeito acumulativo do tratamento.


Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

Now leaving sirtex.com

You are about to leave the Sirtex Website. This link is provided to you as a service and will take you to the Sirtex Virtual Booth.

Sirtex is responsible for the content of the Virtual Booth, which is hosted on a website maintained by a third-party. Except for Sirtex’s Virtual Booth experience, please be aware that Sirtex takes no responsibility for the other content of these external sites, nor do we endorse, warrant, or guarantee the products, services or information described or offered on other internet sites.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×